Saudi-based Amplifai launches AI thermal tool for athletes
Amplifai Health expands AI imaging into sport to track injury recovery
#SaudiArabia #healthcare - Riyadh-based healthtech Amplifai Health has launched NUR, a thermal imaging platform combined with AI that helps athletes and performance staff track recovery, readiness and return-to-play decisions by turning surface temperature patterns into visual data. Launched in Miami, the platform runs through a smart mirror alongside tablet, mobile and web apps, and is currently available to a limited group of early partners including clinics, teams and universities. It marks Amplifai Health’s move from clinical diabetic foot screening into sports performance and wellness.
SO WHAT? - Amplifai Health built its credibility on TFscan, an AI thermal-imaging tool for diabetic care. The product helps cut treatment costs and expand screening capacity and has been cleared by Saudi Arabia’s medical regulator. Applying the same underlying thermal-AI approach to sports recovery tests could take Amplifai into a whole new commercial market, and one driven more by market forces and consumer preferences than medical standards and regulatory approvals.
KEY POINTS:
Amplifai Health launched NUR, a connected Thermal Intelligence platform combining AI and thermal imaging to support athlete recovery, readiness, training and return-to-play decisions.
The platform was launched in Miami, Florida, and is accessible through a NUR smart mirror as well as tablet, mobile and web applications.
Access is currently limited to selected early partners; athletes, clinics, teams, universities and performance organisations can register interest ahead of wider availability.
Pinecrest Physical Therapy, a sports rehabilitation provider serving South Florida and the Caribbean, is collaborating with Amplifai Health on the platform’s early rollout.
NUR builds on Amplifai Health’s existing thermal imaging technology, previously used in TFscan, its AI-powered diabetic foot screening tool approved by the Saudi Food and Drug Authority.
In deployment with Saudi Arabia’s Ministry of Health, TFscan delivered up to an 80% reduction in treatment costs linked to diabetic foot complications and a 12-times increase in screening capacity without a proportional rise in specialist staff.
Amplifai Health’s investors include Wa’ed Ventures, Plug and Play, KAUST Innovation, Techstars and Lamarka.
The company was recently accepted into the World Economic Forum’s MINDS programme, joining a cohort of organisations including Siemens, Lenovo, Sanofi and KPMG recognised for deploying AI with measurable real-world outcomes.
[Written and edited with the assistance of AI]
Source: Amplifai Health